NCT06468852 GDFT on the Postoperative Outcome in Head and Neck Cancer Surgery
| NCT ID | NCT06468852 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tongren Hospital |
| Condition | Postoperative Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 340 participants |
| Start Date | 2024-05-16 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 340 participants in total. It began in 2024-05-16 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether goal-directed fluid therapy (GDFT) can improve the postoperative recovery in patients undergoing head and neck cancer surgery. It aims to answer is: • Whether GDFT can reduce the occurrence of serious postoperative complications? Researchers will compare GDFT protocol to a standard conventional fluid therapy in head and neck cancer surgery to see if GDFT strategy works to improve the postoperative recovery. Participants will * Receive GDFT protocol or a conventional fluid therapy during the surgery. * Be continuously follow-up during hospitalization and after discharge to record the occurrence of postoperative complications.
Eligibility Criteria
Inclusion Criteria: * Adult patients (Age≥18) * Scheduled to undergo head and neck cancer surgery (including nasopharyngeal carcinoma, laryngocarcinoma, hypopharyngeal carcinoma, and other head and neck malignancies, but not thyroid cancer) with an expected duration of 2 hours or longer * Agree to receive invasive artery blood pressure monitoring Exclusion Criteria: * American Society of Anesthesiologists (ASA) classification\>Ⅳ * Palliative surgery was performed for the terminal tumors * Microlaryngoscopic laser surgery or endoscopic surgery * Underwent major thoracic or abdominal surgery within 30 days * Regular renal replacement therapy is required * NYHA grade\>3 or ejection fraction \<30% * Lung disease does not tolerate the tidal volume by 8 ml/kg * Atrial fibrillation * Unable to give informed consent * pregnant or lactating woman * Emergency surgery
Contact & Investigator
Guyan Wang
PRINCIPAL INVESTIGATOR
Beijing Tongren Hospital, CMU
Frequently Asked Questions
Who can join the NCT06468852 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Postoperative Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06468852 currently recruiting?
Yes, NCT06468852 is actively recruiting participants. Contact the research team at doctor_xuan@hotmail.com for enrollment information.
Where is the NCT06468852 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06468852 clinical trial?
NCT06468852 is sponsored by Beijing Tongren Hospital. The principal investigator is Guyan Wang at Beijing Tongren Hospital, CMU. The trial plans to enroll 340 participants.